InMed Pharmaceuticals Inc. Cash Flow Statement
INM|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
InMed Pharmaceuticals Inc. used $7M in operating cash flow and negative free cash flow of $7M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$7.7M | -$7.9M | -$18.6M | -$10.2M |
| Depreciation & Amortization | $219.6K | $202.2K | $185.7K | $120.9K |
| Operating Cash Flow | -$7.0M | -$7.3M | -$15.6M | -$9.8M |
| Capital Expenditures | $9.3K | $160.0K | $39.1K | $1.7K |
| Free Cash Flow | -$7.0M | -$7.4M | -$15.6M | -$9.8M |
| FCF Margin | -152.1% | -180.0% | -1434.0% | -898.9% |